India Pharma Outlook Team | Friday, 10 October 2025
Integris Medtech, recognized as the second largest diversified medical technology platform headquartered in India based on operating revenue for FY25, has submitted its Draft Red Herring Prospectus (DRHP) to the Securities and Exchange Board of India (SEBI), the market regulator.
The initial public offering (IPO) consists of a fresh issuance of equity shares with a face value of Rs. 1 each, totaling up to Rs. 925 crore, alongside an offer for sale of up to 21,674,531 equity shares, also with a face value of Rs. 1. The offer for sale from promoter selling shareholders includes up to 15,174,251 equity shares from Evercure Holdings Pte. Ltd., up to 3,250,140 equity shares from Gurmit Singh Chugh, and up to 3,250,140 equity shares from Punita Sharma.
In collaboration with the Book Running Lead Managers (BRLMs), the company may explore a pre-IPO placement of Rs. 185 crore before submitting the Red Herring Prospectus (RHP) to the Registrar of Companies (ROC).
The company intends to allocate the funds generated from the net proceeds to repay or prepay specific loans, including any interest and prepayment fees totaling Rs. 696.39 crore incurred by its wholly owned subsidiaries and step-down subsidiaries.
Additionally, a portion of the funds will be directed towards general corporate purposes. Co-founded by Gurmit Singh Chugh and Punita Sharma, Integris began its journey with the sale of cardiology products and has progressively evolved into advanced manufacturing, introducing technologies such as the Yukon drug-eluting stent. Recently, the company appointed Probir Das as its CEO, who brings over 26 years of leadership experience in global medtech sectors and has held senior positions at companies like Terumo and Becton Dickinson
